Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. The company is building their transformative engine to identify drug targets and develop a pipeline of antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases. Alchemab Therapeutics was established in 2019 by Uri Laserson and Jane Osbourn in London, England.

Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. It is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the dna.

Carbon Biosciences develops genetic medicines for the treatment of devastating diseases. They develop their vector using industrial-scale viral production platforms and can be used to deliver a wide-range of therapeutic modalities.

Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective. The company creates and validates an FDA cleared instant EEG system that does not require an EEG technologist or specialist interpreter, which allows for faster results and clinical decision-making. The Ceribell EEG System can be set up by any healthcare provider in 6 minutes and offers a proprietary Brain Stethoscope function that dramatically simplifies interpretation of EEG results by converting brainwaves to sound so seizures can be detected by listening. Earlier diagnosis and focused treatment for patients with seizures, including non-convulsive seizures that can only be diagnosed with EEG, can significantly lower mortality, secondary brain injury, length of stay, and risk of complications.

CertiK is a pioneer in blockchain security, leveraging best-in-class AI technology to protect and monitor blockchain protocols and smart contracts. Founded in 2018 by professors from Yale University and Columbia University, CertiK’s mission is to secure the web3 world. CertiK applies cutting-edge innovations from academia to enterprise, enabling mission-critical applications to scale with safety and correctness.

CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already been completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.

Cobo is a globally trusted leader in digital asset custody solutions. Established in 2017 and headquartered in Singapore, our industry-leading custody technologies inspire confidence in digital asset ownership by enabling safe and efficient management of digital assets and interactions with Web 3.0. As a pioneering omni-custody platform, Cobo offers the full spectrum of custody technologies designed specifically to cater to the unique needs of institutions. From full custody based on bank-grade hardware security modules (HSMs), to co-managed custody built on advanced multi-party computation (MPC) technology, and fully decentralized self-custody based on smart contracts, we empower institutions to secure and manage their digital assets their way. In addition, Cobo provides Wallet-as-a-Service, SuperLoop (off-exchange settlement network), and Argus (on-chain DeFi strategies and tools with role-based access controls). Trusted by over 500 institutional clients with billions of dollars in assets under custody, our client base spans across exchanges, mining pools, investment funds, web3 developers, crypto-native firms, to traditional institutions from Asia, Europe, the Middle East, and North and South America. At Cobo, we are committed to security and regulatory compliance. The Company is SOC 2 Type 1 and Type 2 compliance-certified and licensed in the US, Singapore, Hong Kong, Lithuania and Dubai (provisional approval for Virtual Asset License). Cobo is backed by top-tier global investors including DST Global, A&T Capital, IMO Ventures, and DHVC Capital. In September 2021, Cobo completed its USD 40 million Series B financing round.

Cosmos is a project with an ambitious mission: To create a network of distributed ledgers that will solve long-standing problems in the cryptocurrency and blockchain communities.

Darmiyan has developed a novel, proprietary, patent-protected technology called The Virtual Microscope (Software Algorithm). Using a non-invasive routine clinical brain MRI scan, The Virtual Microscope technology looks into the human brain and localizes and quantifies cell distortion (neurodegeneration) in every voxel of brain MRI generating new brain maps. The first clinical product of this technology is BrainSee, an AI-powered algorithm that has completed a successful third-party validation in the US and Canada establishing a remarkable accuracy and consistency for prognosis of mild cognitive impairment. It is built on over 40 years of cutting-edge neuroscience research combined with advanced medical image analysis and AI, and has received official approval from the late Prof. Paul Greengard, Nobel Laureate in Physiology/ Medicine 2000.

The DFINITY Foundation is a not-for-profit organization based in Zurich, Switzerland, that oversees research centers in San Francisco and Zurich. Our mission is to build, promote, and maintain the Internet Computer — and by doing so, improve the world. The Internet Computer extends the functionality of the internet from connecting billions of people to also providing millions of developers and entrepreneurs with a public compute platform — creating a revolutionary new way to build websites, enterprise systems and internet services within an open environment. This public software development platform is created by independent data centers around the world combining computing power using an advanced decentralized protocol called Internet Computer Protocol (ICP). This generational shift in computing aims to take on Big Tech and return the internet back to its free and open roots. DFINITY was founded in 2016 by Dominic Williams.

Engine Biosciences is a biotech company that applies machine learning to genomics for drug discovery. Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. The company's proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications.

Founded in 2018 with offices across three countries and two continents, InfStones is the world's leading blockchain infrastructure provider. Currently, InfStones provides services to large institutional clients around the globe, supporting thousands of nodes on more than 50 public blockchains through its universal platform.